ERBB2 and neoplasm: In the same trial, and another RCT comparing an AI versus AI plus an anti-HER2 therapy, it has been reported that addition of an anti-HER2 targeting agent increases CBR and PFS compared ET alone in HER2+ tumours but not HER2- tumours16–18.